TABLE 1.
Baseline characteristics
| Total = 80 | |
|---|---|
| Age at SLE diagnosis (years), median (IQR) | 29 (21–40) |
| Age at first VTE (years), median (IQR) | 31 (26–51) |
| Sex (female), n (%) | 66 (83) |
| Ethnicity, n (%) | |
| Caucasian | 51 (64) |
| African/Caribbean | 8 (10) |
| Asian | 3 (4) |
| Other | 2 (3) |
| Missing | 16 (20) |
| Type index‐VTE, n (%) | |
| PE with or without DVT | 45 (56) |
| Proximal DVT | 35 (44) |
| Objectively confirmed index VTE, n (%) | 58 (73) |
| SLEDAI‐2K at index‐VTE, median (IQR) | 8 (5–12) |
| Missing, n (%) | 22 (28) |
| Months since SLE diagnosis, median (IQR) | 27 (0–128) |
| Provoked, n (%) | |
| Yes | 40 (50) |
| No | 29 (36) |
| Missing, n (%) | 11 (14) |
| APS, n (%) | |
| Yes | 21 (26) |
| LAC only | 5 |
| AC or B2GP only | 9 |
| LAC + AC or B2GP | 2 |
| Triple | 2 |
| Unknown | 3 |
| No | 55 (69) |
| Missing | 4 (5) |
| Hydroxochloroquine, n (%) | |
| Yes | 20 (25) |
| No | 34 (43) |
| Unknown | 26 (33) |
| Mortality, n (%) | 5 (6) |
| FU time (years), median (IQR) | 8 (3–16) |
Abbreviations: AC, anticardiolipin antibiodies; APS, antiphospholipid syndrome; B2GP, anti‐b2‐glycoprotein antibodies; DVT, deep vein thrombosis; FU, follow‐up; IQR, interquartile range; LAC, lupus anticoagulant; SD, standard deviation; SLE, systemic lupus erythematosus; PE, pulmonary embolism; VTE, venous thromboembolism.